Antibacterial activity of propolis against MRSA and synergism with topical mupirocin
dc.contributor.author | Onlen, Yusuf | |
dc.contributor.author | Duran, Nizami | |
dc.contributor.author | Atik, Esin | |
dc.contributor.author | Savas, Lutfu | |
dc.contributor.author | Altug, Enes | |
dc.contributor.author | Yakan, Selvinaz | |
dc.contributor.author | Aslantas, Ozkan | |
dc.date.accessioned | 2024-09-18T21:05:08Z | |
dc.date.available | 2024-09-18T21:05:08Z | |
dc.date.issued | 2007 | |
dc.department | Hatay Mustafa Kemal Üniversitesi | en_US |
dc.description.abstract | Objectives: The aim of the present study was to investigate the activity of the propolis and its combinations with mupirocin against methicillin-resistant Staphylococcus aureus (MRSA) in nasal carriage. Methods: This study was carried out between June and August 2005. To infect nares of the rabbits, MRSA ( ATCC 33591) strain was used. Minimum inhibitory concentration was determined according to National Committee for Clinical Laboratory Standards. Each inoculum was prepared in the same medium at a density adjusted to a 0.5 McFarland turbidity standard (10(5) colony- forming units [cfu]/ mL) and diluted 1: 100 for the broth microdilution procedure. Ten microliters (10 mu L) (10(5) cfu/mL) of the bacterial suspension containing approximately 1000 cfu of MRSA was administered with sterile microsyringe through both nostrils of each rabbit. Ninety-six ( 96) hours after inoculation, the presence of infection was confirmed by using bacterial cultures. Twenty-six young New Zealand rabbits were randomly divided into 4 groups. Each treatment group ( 1, 2, and 3) included 7 rabbits and control group ( group 4) included 5 rabbits. Group 1 was treated with topical mupirocin + ethanolic extract of propolis drops, group 2 received topical mupirocin, group 3 was administered ethanolic extract of propolis drops, and the control group ( group 4) was only treated with phosphate-buffered solution drops for 7 days. At the end of study, nasal cultures and smears were obtained for bacterial count and cytologic examination. Results: The colony numbers of bacteria in group 1 were determined to be significantly lower than in group 2 (p= 0.0001), group 3 (p = 0.0001), and group 4 ( p = 0.0001). The mean bacterial cell counts of groups 1- 4 were 360.2 +/- 52.4 cfu/ mL, 4120.6 +/- 860.4 cfu/ mL, 5980.8 +/- 1240.6 cfu/ mL, and 11500.0 +/- 2568.4 cfu/ mL, respectively. Mupirocin + propolis administration ( group 1) resulted in a significant reduction in the polymorphonuclear leukocyte (PMNL) count in the mucous membranes of rabbits compared with the other treatment groups ( p < 0.05). Conclusions: Propolis addition to mupirocin regimen was found to result in more profound reduction in bacterial cell count and inflammatory response compared with the rest of the treatment modalities. | en_US |
dc.identifier.doi | 10.1089/acm.2007.7021 | |
dc.identifier.endpage | 718 | en_US |
dc.identifier.issn | 1075-5535 | |
dc.identifier.issn | 1557-7708 | |
dc.identifier.issue | 7 | en_US |
dc.identifier.pmid | 17931063 | en_US |
dc.identifier.scopus | 2-s2.0-35348882897 | en_US |
dc.identifier.scopusquality | N/A | en_US |
dc.identifier.startpage | 713 | en_US |
dc.identifier.uri | https://doi.org/10.1089/acm.2007.7021 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12483/13395 | |
dc.identifier.volume | 13 | en_US |
dc.identifier.wos | WOS:000250191300007 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Mary Ann Liebert, Inc | en_US |
dc.relation.ispartof | Journal of Alternative and Complementary Medicine | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Resistant Staphylococcus-Aureus | en_US |
dc.subject | Nasal Carriage | en_US |
dc.subject | Biological-Properties | en_US |
dc.subject | Intranasal Mupirocin | en_US |
dc.subject | Epidemiology | en_US |
dc.subject | Infections | en_US |
dc.subject | Keratitis | en_US |
dc.subject | Efficacy | en_US |
dc.subject | Growth | en_US |
dc.title | Antibacterial activity of propolis against MRSA and synergism with topical mupirocin | en_US |
dc.type | Article | en_US |
Dosyalar
Orijinal paket
1 - 1 / 1